Front Pharmacol:中草药皂苷对心肌缺血再灌注损伤的保护作用

2021-09-29 August MedSci原创

迄今为止,溶栓等血运重建是治疗急性心肌梗死患者缺血性心肌病的有效方法。然而,再灌注仍会对心肌造成其他损伤,这大大降低了再灌注治疗的优势。因此,

迄今为止,溶栓等血运重建是治疗急性心肌梗死患者缺血性心肌病的有效方法。然而,再灌注仍会对心肌造成其他损伤,这大大降低了再灌注治疗的优势。因此,心肌缺血再灌注损伤(MIRI)是当前亟待关注的临床问题。在过去的三十年中,减少 MIRI 的方法一直在开发中,并已用于临床治疗。治疗方法主要包括非药物干预(缺血预处理)和药物治疗。目前有几种药物在MIRI动物模型中有效,但临床应用并不理想,可能与MIRI病理机制复杂有关。

中医药具有整体治疗理念,具有多靶点、多环节、多途径的优势。在中医领域,MIRI的病因涉及气虚、血瘀、痰多。临床治疗多以中药及复方制剂为主,具有益气养阴、暖心、活血化瘀、祛痰等功效。近年来,许多研究表明,从中药中提取的皂苷具有很大的抗MIRI的影响在体内和体外; 它们的机制多种多样,主要涉及调节能量代谢和钙稳态,抑制氧化应激和炎症。皂苷主要包括四环三萜皂苷和五环三萜皂苷。在四环三萜类皂苷中,达玛烷型皂苷的研究较为深入,而五环三萜类皂苷中,齐墩果烷型皂苷的分布和研究最为广泛。由于其结构特异性,每种皂苷也有其独特的 MIRI 保护机制。此文讨论了 MIRI 的经典机制和一些新兴的调控机制。基于皂苷具有显着的抗MIRI作用,对具有心脏保护作用的皂苷进行了分类总结。

皂苷的作用靶点和抗 MIRI 机制多种多样,主要包括抑制氧化应激、钙超载、炎症和线粒体功能障碍。总之,皂苷具有很强的抗氧化作用,有助于恢复线粒体功能和细胞内钙稳态,减少炎症因子的产生,抑制心肌细胞凋亡,从而发挥心脏保护功能。最近的研究揭示了细胞焦亡和铁死亡在MIRI发病机制中的重要作用。但皂苷对细胞焦亡和铁死亡的影响尚无相关研究。因此,需要进一步研究皂苷对这些新的MIRI机制的调节作用,以完整阐明皂苷对MIRI的保护机制。

从结构上看,具有较强生物活性的皂苷主要是齐墩果酸皂苷和达玛烷型皂苷。研究表明齐墩果酸皂苷对钙稳态具有显着的调节作用,而达玛烷型皂苷对能量代谢的调节作用更为显着。此外,人参皂甙是在达玛烷型皂甙更活跃,而龙牙皂苷在齐墩果酸皂苷中活性更高,这进一步证明中药的独特性是由其关键活性成分的结构决定的。MIRI的发生是一个多因素相互作用、极其复杂的过程;因此,多靶点治疗将是未来药物开发的方向。中药皂苷可同时作用于多种途径,有效降低MIRI。因此,皂苷为开发高效、低毒的抗MIRI药物提供了广阔的应用前景。

目前,皂苷的研究还处于新结构皂苷发现和数据积累的初级阶段。国内外对皂苷抗MIRI构效关系的研究尚处于起步阶段。虽然皂苷的不同生物学活性和作用机制已在分子水平上逐渐阐明,但其临床应用和皂苷治疗 MIRI 的研究还很有限。因此,对皂苷抗MIRI机制的系统总结可能为深入研究皂苷的抗MIRI作用和构效关系奠定基础,从而有助于开发具有新机制或新的抗MIRI药物目标。对皂苷对 MIRI 的构效关系的详细研究将有助于鉴定中药皂苷的活性成分或单体。这最终将有助于通过化学修饰和人工合成开发活性更高、不良反应更少的药物。因此,皂苷的研究将成为抗MIRI药物开发的重要研究方向。

原文:Wang R, Wang M, Zhou J, et al. Saponins in Chinese Herbal Medicine Exerts Protection in Myocardial Ischemia-Reperfusion Injury: Possible Mechanism and Target Analysis. Front Pharmacol. 2021;11:570867. Published 2021 Jan 14. doi:10.3389/fphar.2020.570867

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1754690, encodeId=be111e5469048, content=<a href='/topic/show?id=b5338e217cd' target=_blank style='color:#2F92EE;'>#草药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87217, encryptionId=b5338e217cd, topicName=草药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff5b36776883, createdName=zll0637, createdTime=Tue Aug 02 14:16:45 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763605, encodeId=c3611e63605b9, content=<a href='/topic/show?id=8c323064e09' target=_blank style='color:#2F92EE;'>#再灌注损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30647, encryptionId=8c323064e09, topicName=再灌注损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56da37541085, createdName=ms9833124466084992, createdTime=Sat Mar 26 02:16:45 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788446, encodeId=918a1e8844651, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Tue Feb 15 06:16:45 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036966, encodeId=31c5203696695, content=<a href='/topic/show?id=ad7751320c8' target=_blank style='color:#2F92EE;'>#心肌缺血再灌注损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51320, encryptionId=ad7751320c8, topicName=心肌缺血再灌注损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5eee468, createdName=zxl729, createdTime=Mon Jun 06 09:16:45 CST 2022, time=2022-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996430, encodeId=2e9c199643033, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Nov 16 17:16:45 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908661, encodeId=a01a1908661f4, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Aug 04 01:16:45 CST 2022, time=2022-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066951, encodeId=a3f9106695190, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a3f5473270, createdName=ms9000000466496502, createdTime=Thu Nov 04 15:26:51 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787748, encodeId=fffa1e8774807, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Jan 08 22:16:45 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057346, encodeId=6b98105e346da, content=<a href='/topic/show?id=974e51e2810' target=_blank style='color:#2F92EE;'>#心血管#</a>皂苷的研究将成为抗MIRI药物开发的重要研究方向。, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51728, encryptionId=974e51e2810, topicName=心血管)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTInOuicIVN8Y32NO4Q53Zpd86ObmNp2WIotichCD0qQHaUBeHj7hgwQBCzX7ce4aEw5ZP8icQQfLH9Zw/132, createdBy=4ec21734756, createdName=1def6e10m76(暂无匿称), createdTime=Mon Oct 04 07:26:23 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1398208, encodeId=015a139820859, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Fri Oct 01 14:16:45 CST 2021, time=2021-10-01, status=1, ipAttribution=)]
    2022-08-02 zll0637
  2. [GetPortalCommentsPageByObjectIdResponse(id=1754690, encodeId=be111e5469048, content=<a href='/topic/show?id=b5338e217cd' target=_blank style='color:#2F92EE;'>#草药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87217, encryptionId=b5338e217cd, topicName=草药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff5b36776883, createdName=zll0637, createdTime=Tue Aug 02 14:16:45 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763605, encodeId=c3611e63605b9, content=<a href='/topic/show?id=8c323064e09' target=_blank style='color:#2F92EE;'>#再灌注损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30647, encryptionId=8c323064e09, topicName=再灌注损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56da37541085, createdName=ms9833124466084992, createdTime=Sat Mar 26 02:16:45 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788446, encodeId=918a1e8844651, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Tue Feb 15 06:16:45 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036966, encodeId=31c5203696695, content=<a href='/topic/show?id=ad7751320c8' target=_blank style='color:#2F92EE;'>#心肌缺血再灌注损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51320, encryptionId=ad7751320c8, topicName=心肌缺血再灌注损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5eee468, createdName=zxl729, createdTime=Mon Jun 06 09:16:45 CST 2022, time=2022-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996430, encodeId=2e9c199643033, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Nov 16 17:16:45 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908661, encodeId=a01a1908661f4, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Aug 04 01:16:45 CST 2022, time=2022-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066951, encodeId=a3f9106695190, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a3f5473270, createdName=ms9000000466496502, createdTime=Thu Nov 04 15:26:51 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787748, encodeId=fffa1e8774807, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Jan 08 22:16:45 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057346, encodeId=6b98105e346da, content=<a href='/topic/show?id=974e51e2810' target=_blank style='color:#2F92EE;'>#心血管#</a>皂苷的研究将成为抗MIRI药物开发的重要研究方向。, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51728, encryptionId=974e51e2810, topicName=心血管)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTInOuicIVN8Y32NO4Q53Zpd86ObmNp2WIotichCD0qQHaUBeHj7hgwQBCzX7ce4aEw5ZP8icQQfLH9Zw/132, createdBy=4ec21734756, createdName=1def6e10m76(暂无匿称), createdTime=Mon Oct 04 07:26:23 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1398208, encodeId=015a139820859, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Fri Oct 01 14:16:45 CST 2021, time=2021-10-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1754690, encodeId=be111e5469048, content=<a href='/topic/show?id=b5338e217cd' target=_blank style='color:#2F92EE;'>#草药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87217, encryptionId=b5338e217cd, topicName=草药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff5b36776883, createdName=zll0637, createdTime=Tue Aug 02 14:16:45 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763605, encodeId=c3611e63605b9, content=<a href='/topic/show?id=8c323064e09' target=_blank style='color:#2F92EE;'>#再灌注损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30647, encryptionId=8c323064e09, topicName=再灌注损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56da37541085, createdName=ms9833124466084992, createdTime=Sat Mar 26 02:16:45 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788446, encodeId=918a1e8844651, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Tue Feb 15 06:16:45 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036966, encodeId=31c5203696695, content=<a href='/topic/show?id=ad7751320c8' target=_blank style='color:#2F92EE;'>#心肌缺血再灌注损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51320, encryptionId=ad7751320c8, topicName=心肌缺血再灌注损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5eee468, createdName=zxl729, createdTime=Mon Jun 06 09:16:45 CST 2022, time=2022-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996430, encodeId=2e9c199643033, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Nov 16 17:16:45 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908661, encodeId=a01a1908661f4, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Aug 04 01:16:45 CST 2022, time=2022-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066951, encodeId=a3f9106695190, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a3f5473270, createdName=ms9000000466496502, createdTime=Thu Nov 04 15:26:51 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787748, encodeId=fffa1e8774807, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Jan 08 22:16:45 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057346, encodeId=6b98105e346da, content=<a href='/topic/show?id=974e51e2810' target=_blank style='color:#2F92EE;'>#心血管#</a>皂苷的研究将成为抗MIRI药物开发的重要研究方向。, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51728, encryptionId=974e51e2810, topicName=心血管)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTInOuicIVN8Y32NO4Q53Zpd86ObmNp2WIotichCD0qQHaUBeHj7hgwQBCzX7ce4aEw5ZP8icQQfLH9Zw/132, createdBy=4ec21734756, createdName=1def6e10m76(暂无匿称), createdTime=Mon Oct 04 07:26:23 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1398208, encodeId=015a139820859, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Fri Oct 01 14:16:45 CST 2021, time=2021-10-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1754690, encodeId=be111e5469048, content=<a href='/topic/show?id=b5338e217cd' target=_blank style='color:#2F92EE;'>#草药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87217, encryptionId=b5338e217cd, topicName=草药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff5b36776883, createdName=zll0637, createdTime=Tue Aug 02 14:16:45 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763605, encodeId=c3611e63605b9, content=<a href='/topic/show?id=8c323064e09' target=_blank style='color:#2F92EE;'>#再灌注损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30647, encryptionId=8c323064e09, topicName=再灌注损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56da37541085, createdName=ms9833124466084992, createdTime=Sat Mar 26 02:16:45 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788446, encodeId=918a1e8844651, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Tue Feb 15 06:16:45 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036966, encodeId=31c5203696695, content=<a href='/topic/show?id=ad7751320c8' target=_blank style='color:#2F92EE;'>#心肌缺血再灌注损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51320, encryptionId=ad7751320c8, topicName=心肌缺血再灌注损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5eee468, createdName=zxl729, createdTime=Mon Jun 06 09:16:45 CST 2022, time=2022-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996430, encodeId=2e9c199643033, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Nov 16 17:16:45 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908661, encodeId=a01a1908661f4, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Aug 04 01:16:45 CST 2022, time=2022-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066951, encodeId=a3f9106695190, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a3f5473270, createdName=ms9000000466496502, createdTime=Thu Nov 04 15:26:51 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787748, encodeId=fffa1e8774807, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Jan 08 22:16:45 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057346, encodeId=6b98105e346da, content=<a href='/topic/show?id=974e51e2810' target=_blank style='color:#2F92EE;'>#心血管#</a>皂苷的研究将成为抗MIRI药物开发的重要研究方向。, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51728, encryptionId=974e51e2810, topicName=心血管)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTInOuicIVN8Y32NO4Q53Zpd86ObmNp2WIotichCD0qQHaUBeHj7hgwQBCzX7ce4aEw5ZP8icQQfLH9Zw/132, createdBy=4ec21734756, createdName=1def6e10m76(暂无匿称), createdTime=Mon Oct 04 07:26:23 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1398208, encodeId=015a139820859, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Fri Oct 01 14:16:45 CST 2021, time=2021-10-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1754690, encodeId=be111e5469048, content=<a href='/topic/show?id=b5338e217cd' target=_blank style='color:#2F92EE;'>#草药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87217, encryptionId=b5338e217cd, topicName=草药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff5b36776883, createdName=zll0637, createdTime=Tue Aug 02 14:16:45 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763605, encodeId=c3611e63605b9, content=<a href='/topic/show?id=8c323064e09' target=_blank style='color:#2F92EE;'>#再灌注损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30647, encryptionId=8c323064e09, topicName=再灌注损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56da37541085, createdName=ms9833124466084992, createdTime=Sat Mar 26 02:16:45 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788446, encodeId=918a1e8844651, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Tue Feb 15 06:16:45 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036966, encodeId=31c5203696695, content=<a href='/topic/show?id=ad7751320c8' target=_blank style='color:#2F92EE;'>#心肌缺血再灌注损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51320, encryptionId=ad7751320c8, topicName=心肌缺血再灌注损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5eee468, createdName=zxl729, createdTime=Mon Jun 06 09:16:45 CST 2022, time=2022-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996430, encodeId=2e9c199643033, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Nov 16 17:16:45 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908661, encodeId=a01a1908661f4, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Aug 04 01:16:45 CST 2022, time=2022-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066951, encodeId=a3f9106695190, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a3f5473270, createdName=ms9000000466496502, createdTime=Thu Nov 04 15:26:51 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787748, encodeId=fffa1e8774807, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Jan 08 22:16:45 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057346, encodeId=6b98105e346da, content=<a href='/topic/show?id=974e51e2810' target=_blank style='color:#2F92EE;'>#心血管#</a>皂苷的研究将成为抗MIRI药物开发的重要研究方向。, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51728, encryptionId=974e51e2810, topicName=心血管)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTInOuicIVN8Y32NO4Q53Zpd86ObmNp2WIotichCD0qQHaUBeHj7hgwQBCzX7ce4aEw5ZP8icQQfLH9Zw/132, createdBy=4ec21734756, createdName=1def6e10m76(暂无匿称), createdTime=Mon Oct 04 07:26:23 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1398208, encodeId=015a139820859, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Fri Oct 01 14:16:45 CST 2021, time=2021-10-01, status=1, ipAttribution=)]
    2021-11-16 yb6560
  6. [GetPortalCommentsPageByObjectIdResponse(id=1754690, encodeId=be111e5469048, content=<a href='/topic/show?id=b5338e217cd' target=_blank style='color:#2F92EE;'>#草药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87217, encryptionId=b5338e217cd, topicName=草药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff5b36776883, createdName=zll0637, createdTime=Tue Aug 02 14:16:45 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763605, encodeId=c3611e63605b9, content=<a href='/topic/show?id=8c323064e09' target=_blank style='color:#2F92EE;'>#再灌注损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30647, encryptionId=8c323064e09, topicName=再灌注损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56da37541085, createdName=ms9833124466084992, createdTime=Sat Mar 26 02:16:45 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788446, encodeId=918a1e8844651, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Tue Feb 15 06:16:45 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036966, encodeId=31c5203696695, content=<a href='/topic/show?id=ad7751320c8' target=_blank style='color:#2F92EE;'>#心肌缺血再灌注损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51320, encryptionId=ad7751320c8, topicName=心肌缺血再灌注损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5eee468, createdName=zxl729, createdTime=Mon Jun 06 09:16:45 CST 2022, time=2022-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996430, encodeId=2e9c199643033, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Nov 16 17:16:45 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908661, encodeId=a01a1908661f4, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Aug 04 01:16:45 CST 2022, time=2022-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066951, encodeId=a3f9106695190, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a3f5473270, createdName=ms9000000466496502, createdTime=Thu Nov 04 15:26:51 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787748, encodeId=fffa1e8774807, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Jan 08 22:16:45 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057346, encodeId=6b98105e346da, content=<a href='/topic/show?id=974e51e2810' target=_blank style='color:#2F92EE;'>#心血管#</a>皂苷的研究将成为抗MIRI药物开发的重要研究方向。, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51728, encryptionId=974e51e2810, topicName=心血管)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTInOuicIVN8Y32NO4Q53Zpd86ObmNp2WIotichCD0qQHaUBeHj7hgwQBCzX7ce4aEw5ZP8icQQfLH9Zw/132, createdBy=4ec21734756, createdName=1def6e10m76(暂无匿称), createdTime=Mon Oct 04 07:26:23 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1398208, encodeId=015a139820859, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Fri Oct 01 14:16:45 CST 2021, time=2021-10-01, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1754690, encodeId=be111e5469048, content=<a href='/topic/show?id=b5338e217cd' target=_blank style='color:#2F92EE;'>#草药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87217, encryptionId=b5338e217cd, topicName=草药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff5b36776883, createdName=zll0637, createdTime=Tue Aug 02 14:16:45 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763605, encodeId=c3611e63605b9, content=<a href='/topic/show?id=8c323064e09' target=_blank style='color:#2F92EE;'>#再灌注损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30647, encryptionId=8c323064e09, topicName=再灌注损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56da37541085, createdName=ms9833124466084992, createdTime=Sat Mar 26 02:16:45 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788446, encodeId=918a1e8844651, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Tue Feb 15 06:16:45 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036966, encodeId=31c5203696695, content=<a href='/topic/show?id=ad7751320c8' target=_blank style='color:#2F92EE;'>#心肌缺血再灌注损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51320, encryptionId=ad7751320c8, topicName=心肌缺血再灌注损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5eee468, createdName=zxl729, createdTime=Mon Jun 06 09:16:45 CST 2022, time=2022-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996430, encodeId=2e9c199643033, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Nov 16 17:16:45 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908661, encodeId=a01a1908661f4, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Aug 04 01:16:45 CST 2022, time=2022-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066951, encodeId=a3f9106695190, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a3f5473270, createdName=ms9000000466496502, createdTime=Thu Nov 04 15:26:51 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787748, encodeId=fffa1e8774807, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Jan 08 22:16:45 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057346, encodeId=6b98105e346da, content=<a href='/topic/show?id=974e51e2810' target=_blank style='color:#2F92EE;'>#心血管#</a>皂苷的研究将成为抗MIRI药物开发的重要研究方向。, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51728, encryptionId=974e51e2810, topicName=心血管)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTInOuicIVN8Y32NO4Q53Zpd86ObmNp2WIotichCD0qQHaUBeHj7hgwQBCzX7ce4aEw5ZP8icQQfLH9Zw/132, createdBy=4ec21734756, createdName=1def6e10m76(暂无匿称), createdTime=Mon Oct 04 07:26:23 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1398208, encodeId=015a139820859, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Fri Oct 01 14:16:45 CST 2021, time=2021-10-01, status=1, ipAttribution=)]
    2021-11-04 ms9000000466496502

    学习学习

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1754690, encodeId=be111e5469048, content=<a href='/topic/show?id=b5338e217cd' target=_blank style='color:#2F92EE;'>#草药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87217, encryptionId=b5338e217cd, topicName=草药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff5b36776883, createdName=zll0637, createdTime=Tue Aug 02 14:16:45 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763605, encodeId=c3611e63605b9, content=<a href='/topic/show?id=8c323064e09' target=_blank style='color:#2F92EE;'>#再灌注损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30647, encryptionId=8c323064e09, topicName=再灌注损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56da37541085, createdName=ms9833124466084992, createdTime=Sat Mar 26 02:16:45 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788446, encodeId=918a1e8844651, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Tue Feb 15 06:16:45 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036966, encodeId=31c5203696695, content=<a href='/topic/show?id=ad7751320c8' target=_blank style='color:#2F92EE;'>#心肌缺血再灌注损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51320, encryptionId=ad7751320c8, topicName=心肌缺血再灌注损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5eee468, createdName=zxl729, createdTime=Mon Jun 06 09:16:45 CST 2022, time=2022-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996430, encodeId=2e9c199643033, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Nov 16 17:16:45 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908661, encodeId=a01a1908661f4, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Aug 04 01:16:45 CST 2022, time=2022-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066951, encodeId=a3f9106695190, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a3f5473270, createdName=ms9000000466496502, createdTime=Thu Nov 04 15:26:51 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787748, encodeId=fffa1e8774807, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Jan 08 22:16:45 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057346, encodeId=6b98105e346da, content=<a href='/topic/show?id=974e51e2810' target=_blank style='color:#2F92EE;'>#心血管#</a>皂苷的研究将成为抗MIRI药物开发的重要研究方向。, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51728, encryptionId=974e51e2810, topicName=心血管)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTInOuicIVN8Y32NO4Q53Zpd86ObmNp2WIotichCD0qQHaUBeHj7hgwQBCzX7ce4aEw5ZP8icQQfLH9Zw/132, createdBy=4ec21734756, createdName=1def6e10m76(暂无匿称), createdTime=Mon Oct 04 07:26:23 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1398208, encodeId=015a139820859, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Fri Oct 01 14:16:45 CST 2021, time=2021-10-01, status=1, ipAttribution=)]
    2022-01-08 jj000001
  9. [GetPortalCommentsPageByObjectIdResponse(id=1754690, encodeId=be111e5469048, content=<a href='/topic/show?id=b5338e217cd' target=_blank style='color:#2F92EE;'>#草药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87217, encryptionId=b5338e217cd, topicName=草药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff5b36776883, createdName=zll0637, createdTime=Tue Aug 02 14:16:45 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763605, encodeId=c3611e63605b9, content=<a href='/topic/show?id=8c323064e09' target=_blank style='color:#2F92EE;'>#再灌注损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30647, encryptionId=8c323064e09, topicName=再灌注损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56da37541085, createdName=ms9833124466084992, createdTime=Sat Mar 26 02:16:45 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788446, encodeId=918a1e8844651, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Tue Feb 15 06:16:45 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036966, encodeId=31c5203696695, content=<a href='/topic/show?id=ad7751320c8' target=_blank style='color:#2F92EE;'>#心肌缺血再灌注损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51320, encryptionId=ad7751320c8, topicName=心肌缺血再灌注损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5eee468, createdName=zxl729, createdTime=Mon Jun 06 09:16:45 CST 2022, time=2022-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996430, encodeId=2e9c199643033, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Nov 16 17:16:45 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908661, encodeId=a01a1908661f4, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Aug 04 01:16:45 CST 2022, time=2022-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066951, encodeId=a3f9106695190, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a3f5473270, createdName=ms9000000466496502, createdTime=Thu Nov 04 15:26:51 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787748, encodeId=fffa1e8774807, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Jan 08 22:16:45 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057346, encodeId=6b98105e346da, content=<a href='/topic/show?id=974e51e2810' target=_blank style='color:#2F92EE;'>#心血管#</a>皂苷的研究将成为抗MIRI药物开发的重要研究方向。, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51728, encryptionId=974e51e2810, topicName=心血管)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTInOuicIVN8Y32NO4Q53Zpd86ObmNp2WIotichCD0qQHaUBeHj7hgwQBCzX7ce4aEw5ZP8icQQfLH9Zw/132, createdBy=4ec21734756, createdName=1def6e10m76(暂无匿称), createdTime=Mon Oct 04 07:26:23 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1398208, encodeId=015a139820859, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Fri Oct 01 14:16:45 CST 2021, time=2021-10-01, status=1, ipAttribution=)]
    2021-10-04 1def6e10m76(暂无匿称)

    #心血管#皂苷的研究将成为抗MIRI药物开发的重要研究方向。

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1754690, encodeId=be111e5469048, content=<a href='/topic/show?id=b5338e217cd' target=_blank style='color:#2F92EE;'>#草药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87217, encryptionId=b5338e217cd, topicName=草药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff5b36776883, createdName=zll0637, createdTime=Tue Aug 02 14:16:45 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763605, encodeId=c3611e63605b9, content=<a href='/topic/show?id=8c323064e09' target=_blank style='color:#2F92EE;'>#再灌注损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30647, encryptionId=8c323064e09, topicName=再灌注损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56da37541085, createdName=ms9833124466084992, createdTime=Sat Mar 26 02:16:45 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788446, encodeId=918a1e8844651, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Tue Feb 15 06:16:45 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036966, encodeId=31c5203696695, content=<a href='/topic/show?id=ad7751320c8' target=_blank style='color:#2F92EE;'>#心肌缺血再灌注损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51320, encryptionId=ad7751320c8, topicName=心肌缺血再灌注损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5eee468, createdName=zxl729, createdTime=Mon Jun 06 09:16:45 CST 2022, time=2022-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996430, encodeId=2e9c199643033, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Nov 16 17:16:45 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908661, encodeId=a01a1908661f4, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Aug 04 01:16:45 CST 2022, time=2022-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066951, encodeId=a3f9106695190, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a3f5473270, createdName=ms9000000466496502, createdTime=Thu Nov 04 15:26:51 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787748, encodeId=fffa1e8774807, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Jan 08 22:16:45 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057346, encodeId=6b98105e346da, content=<a href='/topic/show?id=974e51e2810' target=_blank style='color:#2F92EE;'>#心血管#</a>皂苷的研究将成为抗MIRI药物开发的重要研究方向。, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51728, encryptionId=974e51e2810, topicName=心血管)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTInOuicIVN8Y32NO4Q53Zpd86ObmNp2WIotichCD0qQHaUBeHj7hgwQBCzX7ce4aEw5ZP8icQQfLH9Zw/132, createdBy=4ec21734756, createdName=1def6e10m76(暂无匿称), createdTime=Mon Oct 04 07:26:23 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1398208, encodeId=015a139820859, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Fri Oct 01 14:16:45 CST 2021, time=2021-10-01, status=1, ipAttribution=)]

相关资讯

Sci Signal:中药蛇床子登上Science子刊封面,我国学者证实蛇床子可舒张气道、抑制哮喘,并解析其分子机制

气道高反应性是指气道对多种刺激因子出现过强或过早的收缩反应,这一症状在哮喘病人中尤为常见,严重时可导致病人呼吸困难。常规使用的肾上腺素受体激动剂虽可有效抑制气道高反应性,但容易产生耐药反应。

Clinical Evidence From Randomized Controlled Trials:中医治疗冠状动脉疾病

近年来,由于各种原因,诸如人口老龄化,心血管疾病的数量急剧上升。与心血管疾病相关的死亡率也在全球范围内迅速上升,给全球健康带来了巨大威胁。

Biomed Pharmacother:中医药联合肺部给药系统防治特发性肺纤维化可行性探讨

特发性肺纤维化 (IPF) 是一种病因不明的进行性肺间质炎性疾病,也是冠状病毒病重症患者的后遗症。中医药作为一种独特的医学疗法,通过多层次、多靶点的方法,在全球范围内逐渐发挥其在IPF治疗中的优势。

Circulation:中药天麻-钩藤颗粒有效治疗隐匿性高血压!

虽然,众所周知,隐匿性高血压与心血管预后不良相关,但目前仍无关于隐匿性高血压治疗的随机试验。本研究是一项随机、安慰剂为对照的临床试验,旨在研究隐匿性高血压患者采用中药天麻-钩藤颗粒降血压(BP)治疗的

金匮肾气丸、六味地黄丸、右归丸,肾虚应该如何选择?一文讲清楚

金匮肾气丸、六味地黄丸、右归丸都是补肾益气的良药,各自的成分和适应症都有所不同。虽然对身体都有益,但毕竟是药,健康人群不需服用。即使是有疾病的人群,在痊愈后也应停止服用。

中医药防治大肠癌得新突破:曙光医院李琦教授团队采用中医药降低了大肠癌术后转移率

李琦教授团队证实中药复方可有效预防III期大肠癌术后复发转移,提高患者无病生存期,改善生活质量